Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial

Stefano Barco, Tim Sebastian, Davide Voci, Rolf Peter Engelberger, Alexandru Grigorean, Erik Holy, Claudia Leeger, Mario Münger, Daniel Périard, Eliane Probst, Rebecca Spescha, Ulrike Held, Nils Kucher, Stefano Barco, Tim Sebastian, Davide Voci, Rolf Peter Engelberger, Alexandru Grigorean, Erik Holy, Claudia Leeger, Mario Münger, Daniel Périard, Eliane Probst, Rebecca Spescha, Ulrike Held, Nils Kucher

Abstract

Background: Peripheral arterial disease is a progressive atherosclerotic disease with symptoms ranging from an intermittent claudication to acute critical limb ischemia and amputations. Drug-coated balloons and stents were developed to prevent neo-intimal proliferation and restenosis after percutaneous transluminal angioplasty. Randomized controlled trials showed that drug-coated, notably paclitaxel-coated, devices reduce restenosis, late lumen loss, and the need for target lesion re-vascularization compared with uncoated ones. However, the size of these trials was too small to prove superiority for "hard" clinical outcomes. Moreover, available studies were characterized by too restrictive eligibility criteria. Finally, it remains unclear whether paclitaxel-coated balloons may impair long-term survival. Alternative drug-coated balloons, the so-called limus-based analogs, have been approved for clinical use in patients with peripheral arterial disease. By encapsulating sirolimus in phospholipid drug nanocarriers, they optimize adhesion properties of sirolimus and provide better bioavailability.

Methods: In this investigator-initiated all-comer open-label phase III randomized controlled trial, we will evaluate whether sirolimus-coated balloon angioplasty is non-inferior and eventually superior, according to a predefined hierarchical analysis, to uncoated balloon angioplasty in adults with infra-inguinal peripheral arterial disease requiring endovascular angioplasty. Key exclusion criteria are pregnancy or breastfeeding, known intolerance or allergy to sirolimus, and participation in a clinical trial during the previous 3 months. The primary efficacy outcome is the composite of two clinically relevant non-subjective "hard" outcomes: unplanned major amputation of the target limb and endovascular or surgical target lesion re-vascularization for critical limb ischemia occurring within 1 year of randomization. The primary safety outcome includes death from all causes.

Discussion: By focusing on clinically relevant outcomes, this study will provide useful information on the efficacy and safety of sirolimus-coated balloon catheters for infra-inguinal peripheral arterial disease in a representative ("all-comer") population of unselected patients. As regulatory agencies had raised safety concerns in patients exposed to paclitaxel-coated devices (versus uncoated ones), collect mortality data up to 5 years after randomization will be collected.

Trial registration: ClinicalTrials.gov NCT04238546.

Keywords: Atherosclerotic disease; Common iliac artery; Covered stent; Critical limb ischemia; Endovascular; Intermittent claudication; Peripheral arterial occlusive disease; Sirolimus; Stenting.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Temporal penetration of labeled sirolimus nanoparticles
Fig. 2
Fig. 2
Tissue concentration of sirolimus after single 60-s inflation
Fig. 3
Fig. 3
Participant timeline
Fig. 4
Fig. 4
Study recruitment

References

    1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–e1030. doi: 10.1016/S2214-109X(19)30255-4.
    1. European Stroke O, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC) Eur Heart J. 2011;32(22):2851–2906. doi: 10.1093/eurheartj/ehr211.
    1. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS, Zilver PTX Investigators Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504. doi: 10.1161/CIRCINTERVENTIONS.111.962324.
    1. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–153. doi: 10.1056/NEJMoa1406235.
    1. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–19. doi: 10.1016/j.jcin.2013.05.022.
    1. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M, Snead DB, Kent KC, Rocha-Singh KJ, IN.PACT DEEP Trial Investigators Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64(15):1568–1576. doi: 10.1016/j.jacc.2014.06.1198.
    1. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR, IN.PACT SFA Trial Investigators Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502. doi: 10.1161/CIRCULATIONAHA.114.011004.
    1. Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701–707. doi: 10.1177/1526602816650206.
    1. Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E, Sixt S, Schwarz T, Brechtel K, Bohme C, Neumann FJ, Zeller T. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–2281. doi: 10.1093/eurheartj/ehr144.
    1. Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgräber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;17(16):42–50. doi: 10.1016/j.eclinm.2019.09.004.
    1. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245. doi: 10.1161/JAHA.118.011245.
    1. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HMM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9(1):148–156. doi: 10.4244/EIJV9I1A21.
    1. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, Murad MH. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62(6):1642–1651 e1643. doi: 10.1016/j.jvs.2015.07.065.
    1. Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR, Complete SE Investigators Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014;21(2):202–212. doi: 10.1583/13-4548R.1.
    1. Klaphake S, de Leur K, Thijsse W, Ho GH, de Groot HGW, Veen EJ, Haans DHAW, van der Laan L. Reinterventions after endovascular revascularization in elderly patients with critical limb ischemia: an observational study. Ann Vasc Surg. 2018;53:171–176. doi: 10.1016/j.avsg.2018.04.021.
    1. Grip O, Wanhainen A, Acosta S, Bjorck M. Long-term outcome after thrombolysis for acute lower limb ischaemia. Eur J Vasc Endovasc Surg. 2017;53(6):853–861. doi: 10.1016/j.ejvs.2017.02.003.
    1. Byrne RM, Taha AG, Avgerinos E, Marone LK, Makaroun MS, Chaer RA. Contemporary outcomes of endovascular interventions for acute limb ischemia. J Vasc Surg. 2014;59(4):988–995. doi: 10.1016/j.jvs.2013.10.054.
    1. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338(16):1105–1111. doi: 10.1056/NEJM199804163381603.
    1. Hess CN, Rogers RK, Wang TY, Fu R, Gundrum J, Allen LaPointe NM, Hiatt WR. Major adverse limb events and 1-year outcomes after peripheral artery revascularization. J Am Coll Cardiol. 2018;72(9):999–1011. doi: 10.1016/j.jacc.2018.06.041.
    1. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, SALA J, CARTASEGNA L, VICO M, HOMINAL MA, HASBANI E, CACCAVO A, ZAIDMAN C, VOGEL D, HRABAR A, SCHYGIEL PO, CUNEO C, LUQUEZ H, MACKINNON IJ, AHUAD GUERRERO RA, COSTABEL JP, BARTOLACCI IP, MONTANA O, BARBIERI M, GOMEZ VILAMAJO O, GARCIA DURAN RO, SCHIAVI LB, GARRIDO M, INGARAMO A, BORDONAVA AP, PELAGAGGE MJ, NOVARETTO L, ALBISU di GENNERO JUANPABLO, IBANEZ SAGGIA LM, ALVAREZ M, VITA NA, MACIN SM, DRAN RD, CARDONA M, GUZMAN L, SARJANOVICH RJ, CUADRADO J, NANI S, LITVAK BRUNO MR, CHACON C, MAFFEI LE, GRINFELD D, VENSENTINI N, MAJUL CR, LUCIARDI HL, GONZALEZ COLASO PDC, FERRE PACORA FA, van den HEUVEL P, VERHAMME P, ECTOR B, DEBONNAIRE P, van de BORNE P, LEROY J, SCHROE H, VRANCKX P, ELEGEERT I, HOFFER E, DUJARDIN K, INDIO DO BRASIL C, PRECOMA D, ABRANTES JA, MANENTI E, REIS G, SARAIVA J, MAIA L, HERNANDES M, ROSSI P, ROSSI DOS SANTOS F, ZIMMERMANN SL, RECH R, ABIB JR E, LEAES P, BOTELHO R, DUTRA O, SOUZA W, BRAILE M, IZUKAWA N, NICOLAU JC, TANAJURA LF, SERRANO JUNIOR CV, MINELLI C, NASI LA, OLIVEIRA L, de CARVALHO CANTARELLI MARCELOJOSE, TYTUS R, PANDEY S, LONN E, CHA J, VIZEL S, BABAPULLE M, LAMY A, SAUNDERS K, BERLINGIERI J, KIAII B, BHARGAVA R, MEHTA P, HILL L, FELL D, LAM A, al-QOOFI FAISAL, BROWN C, PETRELLA R, RICCI JA, GLANZ A, NOISEUX N, BAINEY K, MERALI F, HEFFERNAN M, DELLA SIEGA A, DAGENAIS GR, DAGENAIS F, BRULOTTE S, NGUYEN M, HARTLEIB M, GUZMAN R, BOURGEOIS R, RUPKA D, KHAYKIN Y, GOSSELIN G, HUYNH T, PILON C, CAMPEAU J, PICHETTE F, DIAZ A, JOHNSTON J, SHUKLE P, HIRSCH G, RHEAULT P, CZARNECKI W, ROY A, NAWAZ S, FREMES S, SHUKLA D, JANO G, COBOS JL, CORBALAN R, MEDINA M, NAHUELPAN L, RAFFO C, PEREZ L, POTTHOFF S, STOCKINS B, SEPULVEDA P, PINCETTI C, VEJAR M, TIAN H, WU X, KE Y, JIA K, YIN P, WANG Z, YU L, WU S, WU Z, LIU SW, BAI XJ, ZHENG Y, YANG P, YANG YM, ZHANG J, GE J, CHEN XP, LI J, HU TH, ZHANG R, ZHENG Z, CHEN X, TAO L, LI J, HUANG W, FU G, LI C, DONG Y, WANG C, ZHOU X, KONG Y, SOTOMAYOR A, ACCINI MENDOZA JL, CASTILLO H, URINA M, AROCA G, PEREZ M, MOLINA de SALAZAR DORAINES, SANCHEZ VALLEJO G, FERNANDO MJ, GARCIA H, GARCIA LH, ARCOS E, GOMEZ J, CUERVO MILLAN F, TRUJILLO DADA FA, VESGA B, MORENO SILGADO GA, ZIDKOVA E, LUBANDA JC, KALETOVA M, KRYZA R, MARCINEK G, RICHTER M, SPINAR J, MATUSKA J, TESAK M, MOTOVSKA Z, BRANNY M, MALY J, MALY M, WIENDL M, FOLTYNOVA CAISOVA L, SLABY J, VOJTISEK P, PIRK J, SPINAROVA L, BENESOVA M, CANADYOVA J, HOMZA M, FLORIAN J, POLASEK R, COUFAL Z, SKALNIKOVA V, BRAT R, BRTKO M, JANSKY P, LINDNER J, MARCIAN P, STRAKA Z, TRETINA M, DUARTE YC, POW CHON LONG F, SANCHEZ M, LOPEZ J, PERUGACHI C, MARMOL R, TRUJILLO F, TERAN P, TUOMILEHTO J, TUOMILEHTO H, TUOMINEN ML, TUOMILEHTO H, KANTOLA I, STEG G, ABOYANS V, LECLERCQ F, FERRARI E, BOCCARA F, MESSAS E, MISMETTI P, SEVESTRE MA, CAYLA G, MOTREFF P, STOERK S, DUENGEN HD, STELLBRINK C, GUEROCAK O, KADEL C, BRAUN-DULLAEUS R, JESERICH M, OPITZ C, VOEHRINGER HF, APPEL KF, WINKELMANN B, DORSEL T, NIKOL S, DARIUS H, RANFT J, SCHELLONG S, JUNGMAIR W, DAVIERWALA P, VORPAHL M, BAJNOK L, LASZLO Z, NOORI E, VERESS G, VERTES A, ZSARY A, KIS E, KORANYI L, BAKAI J, BODA Z, POOR F, JARAI Z, KEMENY V, BARTON J, MCADAM B, MURPHY A, CREAN P, MAHON N, CURTIN R, MACNEILL B, DINNEEN S, HALABI M, ZIMLICHMAN R, ZELTSER D, TURGEMAN Y, KLAINMAN E, LEWIS B, KATZ A, ATAR S, ZIMLICHMAN R, NIKOLSKY E, BOSI S, NALDI M, FAGGIANO P, ROBBA D, MOS L, SINAGRA G, COSMI F, OLTRONA VISCONTI L, CARMINE DM, di PASQUALE GIUSEPPE, di BIASE MATTEO, MANDORLA S, BERNARDINANGELI M, PICCINNI GC, GULIZIA MM, GALVANI M, VENTURI F, MOROCUTTI G, BALDIN MG, OLIVIERI C, PERNA GP, CIRRINCIONE V, KANNO T, DAIDA H, OZAKI Y, MIYAMOTO N, HIGASHIUE S, DOMAE H, HOSOKAWA S, KOBAYASHI H, KURAMOCHI T, FUJII K, MIZUTOMI K, SAKU K, KIMURA K, HIGUCHI Y, ABE M, OKUDA H, NODA T, MITA T, HIRAYAMA A, ONAKA H, INOKO M, HIROKAMI M, OKUBO M, AKATSUKA Y, IMAMAKI M, KAMIYA H, MANITA M, HIMI T, UENO H, HISAMATSU Y, AKO J, NISHINO Y, KAWAKAMI H, YAMADA Y, KORETSUNE Y, YAMADA T, YOSHIDA T, SHIMOMURA H, KINOSHITA N, TAKAHASHI A, YUSOFF K, WAN AHMAD WA, ABU HASSAN MR, KASIM S, ABDUL RAHIM AA, MOHD ZAMRIN D, MACHIDA M, HIGASHINO Y, UTSU N, NAKANO A, NAKAMURA S, HASHIMOTO T, ANDO K, SAKAMOTO T, PRINS FJ, LOK D, MILHOUS JGJ, VIERGEVER E, WILLEMS F, SWART H, ALINGS M, BREEDVELD R, de VRIES KEESJAN, van der BORGH R, OEI F, ZOET-NUGTEREN S, KRAGTEN H, HERRMAN JP, van BERGEN P, GOSSELINK M, HOEKSTRA E, ZEGERS E, RONNER E, den HARTOG F, BARTELS G, NIEROP P, van der ZWAAN C, van ECK J, van GORSELEN E, GROENEMEIJER B, HOOGSLAG P, de GROOT MARCROBERT, LOYOLA A, SULIT DJ, REY N, ABOLA MT, MORALES D, PALOMARES E, ABAT ME, ROGELIO G, CHUA P, del PILAR JC, ALCARAZ JD, EBO G, TIRADOR L, CRUZ J, ANONUEVO J, PITARGUE A, JANION M, GUZIK T, GAJOS G, ZABOWKA M, RYNKIEWICZ A, BRONCEL M, SZUBA A, CZARNECKA D, MAGA P, STRAZHESKO I, VASYUK Y, SIZOVA Z, POZDNYAKOV Y, BARBARASH O, VOEVODA M, POPONINA T, REPIN A, OSIPOVA I, EFREMUSHKINA A, NOVIKOVA N, AVERKOV O, ZATEYSHCHIKOV D, VERTKIN A, AUSHEVA A, COMMERFORD P, SEEDAT S, van ZYL L, ENGELBRECHT J, MAKOTOKO EM, PRETORIUS CE, MOHAMED Z, HORAK A, MABIN T, KLUG E, BAE JH, KIM C, KIM CJ, KIM DS, KIM YJ, JOO S, HA JW, PARK CS, KIM JY, KIM YK, JARNERT C, MOOE T, DELLBORG M, TORSTENSSON I, ALBERTSSON P, JOHANSSON L, al-KHALILI FARIS, ALMROTH H, ANDERSSON T, PANTEV E, TENGMARK BO, LIU B, RASMANIS G, WAHLGREN CM, MOCCETTI T, PARKHOMENKO A, TSELUYKO V, VOLKOV V, KOVAL O, KONONENKO L, PROKHOROV O, VDOVYCHENKO V, BAZYLEVYCH A, RUDENKO L, VIZIR V, KARPENKO O, MALYNOVSKY Y, KOVAL V, STOROZHUK B, COTTON J, VENKATARAMAN A, MORIARTY A, CONNOLLY D, DAVEY P, SENIOR R, BIRDI I, CALVERT J, DONNELLY P, TREVELYAN J, CARTER J, PEACE A, AUSTIN D, KUKREJA N, HILTON T, SRIVASTAVA S, WALSH R, FIELDS R, HAKAS J, PORTNAY E, GOGIA H, SALACATA A, HUNTER JJ, BACHARACH JM, SHAMMAS N, SURESH D, SCHNEIDER R, GURBEL P, BANERJEE S, GRENA P, BEDWELL N, SLOAN S, LUPOVITCH S, SONI A, GIBSON K, SANGRIGOLI R, MEHTA R, I-HSUAN TSAI P, GILLESPIE E, DEMPSEY S, HAMROFF G, BLACK R, LADER E, KOSTIS JB, BITTNER V, MCGUINN W, BRANCH K, MALHOTRA V, MICHAELSON S, VACANTE M, MCCORMICK M, ARIMIE R, CAMP A, DAGHER G, KOSHY NM, THEW S, COSTELLO F, HEIMAN M, CHILTON R, MORAN M, ADLER F, COMEROTA A, SEIWERT A, FRENCH W, SEROTA H, HARRISON R, BAKAEEN F, OMER S, CHANDRA L, WHELAN A, BOYLE A, ROBERTS-THOMSON P, ROGERS J, CARROLL P, COLQUHOUN D, SHAW J, BLOMBERY P, AMERENA J, HII C, ROYSE A, SINGH B, SELVANAYAGAM J, JANSEN S, LO W, HAMMETT C, POULTER R, NARASIMHAN S, WIGGERS H, NIELSEN H, GISLASON G, KOBER L, HOULIND K, BOENELYKKE SOERENSEN V, DIXEN U, REFSGAARD J, ZEUTHEN E, SOEGAARD P, HRANAI M, GASPAR L, PELLA D, HATALOVA K, DROZDAKOVA E, COMAN I, DIMULESCU D, VINEREANU D, CINTEZA M, SINESCU C, ARSENESCU C, BENEDEK I, BOBESCU E, DOBREANU D, GAITA D, IANCU A, ILIESIU A, LIGHEZAN D, PETRESCU L, PIRVU O, TEODORESCU I, TESLOIANU D, VINTILA MM, CHIONCEL O. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1.
    1. Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Jr, Robinson WP. Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. J Vasc Surg. 2018;68(6):1817–1823. doi: 10.1016/j.jvs.2018.06.193.
    1. Mehaffey JH, Hawkins RB, Fashandi A, Cherry KJ, Kern JA, Kron IL, Upchurch GR, Jr, Robinson WP. Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention. J Vasc Surg. 2017;66(4):1109–1116 e1101. doi: 10.1016/j.jvs.2017.04.036.
    1. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Circulation. 2018;137(4):338–350. doi: 10.1161/CIRCULATIONAHA.117.032235.
    1. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306–2315. doi: 10.1016/j.jacc.2018.03.008.
    1. D'Agostino RB, Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169–186. doi: 10.1002/sim.1425.
    1. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337–2343. doi: 10.1001/jama.2017.18556.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する